

27 October 2014

L.J. Tan, PhD
Chair National Adult and Influenza Vaccine Summit
Chief Strategy Officer I.A.C

By email

Dear L.J.


I'm pleased to share with you that CSL has today announced an agreement to purchase Novartis' global influenza vaccine business, which will be integrated with and operated as part of bioCSL.

The acquisition will create the second largest vaccine company in the global influenza industry with facilities in the US, UK, Germany and Australia, and a comprehensive portfolio of differentiated influenza vaccines. The combined entity will also have enhanced pre-pandemic and pandemic capabilities in our primary centres of operation.

The acquisition is expected to be completed within the second half of 2015.

bioCSL has a long and proud history in the development and manufacture of influenza vaccines and a strong track record in production and supply of virus reassortants and reagents for the WHO. The acquisition of the Novartis business will enable us to make an even greater contribution to the prevention and control of influenza.

Kind regards



Marie Mazur, Pharm.D
President bioCSL Inc & Head of Worldwide Commercial Operations, Influenza